Clinical trials: Cancer of Nasopharynx
Nasopharyngeal Carcinoma, Head and Neck Cancer
Exploratory Study of EBV DNA Titre Clearance Whilst on Proton Beam Therapy
How does plasma Epstein-Barr Virus (EBV) DNA level change during definitive radiation therapy for nasopharyngeal carcinoma (NPC) in the teenage and young adult cohort and does it correlate with outcomes?
- Conditions
- Nasopharyngeal Carcinoma, Head and Neck Cancer, Nasopharyngeal Cancer, Epstein-Barr Virus
- Trial name
- ClearED (NCT06480903)
- Volunteers
- 10 people
- Sponsor
- The Christie NHS Foundation Trust
Liver Injury, Drug-Induced
Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury
The most common toxicity of TP (docetaxel and cisplatin) chemotherapy is chemotherapy-induced liver injury. However, patients don't always experience same chemotherapy-induced liver injury for the same drugs.
- Trial name
- NCT03069820
- Testing
- docetaxel and cisplatin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Nasopharyngeal Carcinoma
Olfactory Change After Chemo-radiotherapy for Nasopharyngeal Carcinoma
This is an observational cohort study aimed to explore the changes of olfactory function at multiple time points from baseline to 1 year after radiotherapy among the local advanced nasopharyngeal carcinoma patients.
- Trial name
- NCT05146050
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00248560
- Testing
- docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Nasopharyngeal Carcinoma
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
The purpose of this study is to compare concurrent chemoradiotherapy (CCRT) alone with induction chemotherapy (gemcitabine+cisplatin) plus CCRT in patients with low-risk locoregionally advanced nasopharyngeal carcinoma(NPC).
- Trial name
- NCT05979961
- Testing
- IMRT and concurrent cisplatin, gemcitabine and cisplatin (Induction chemotherapy)
- Where
- 8 sites in China
- Volunteers
- 464 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be an effective palliative treatment for head and neck cancer.
- Trial name
- NCT00003856
- Testing
- temoporfin
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- Quintiles, Inc.
Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma
Stereotactic Body Radiotherapy for Head and Neck Tumors
This study will evaluate the local control rates as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of benign and malignant head and neck tumors.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Salivary Gland Cancer, Head and Neck Sarcoma
- Trial name
- NCT01344356
- Testing
- stereotactic body radiotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mercy Research
Artificial Intelligence Supported Image Reviewing
Artificial Intelligence-supported Reading Versus Standard Double Reading for the Interpretation of Magnetic Resonance Imaging in the Detection of Local Recurrence for Nasopharyngeal Carcinoma: a Randomised Controlled Multicenter Study
The aim of this randomized controlled study is to investigate whether the previously developed artificial intelligence model can triage post-radiotherapy magnetic resonance images of patients with nasopharyngeal carcinoma and…
- Trial name
- NCT06356441
- Testing
- AI
- Where
- China
- Volunteers
- 10,400 people
- Sponsor
- Sun Yat-sen University
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases
Patients have a type of a lymph node cancer called lymphoma, a tumor of the nasal passages called nasopharyngeal carcinoma (NPC), a tumor of a particular type of muscle called leiomyosarcoma (LMS) or a condition called severe…
- Conditions
- Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoproliferative Disorder, Nasopharyngeal Carcinoma
- Trial name
- MALTED (NCT01447056)
- Testing
- LMP specific T cells
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Baylor College of Medicine
Nasopharyngeal Carcinoma
Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
To prospectively evaluate the short-term efficacy and toxicity of induction chemotherapy with cisplatin and capecitabine followed by concurrent chemoradiotherapy (CCRT) in the treatment of locally advanced nasopharyngeal…
- Trial name
- NCT03427359
- Testing
- cisplatin, capecitabine
- Volunteers
- 65 people
- Sponsor
- The University of Hong Kong-Shenzhen Hospital
Recurrent or Metastatic Nasopharyngeal Carcinoma
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- Magic-C002 (NCT06976190)
- Testing
- MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma
This is a single-center, single-arm, phase II clinical trial designed to evaluate the efficacy and safety of becotatug vedotin combined with gemcitabine and a PD-1 inhibitor as second-line or later treatment for patients with…
- Trial name
- NCT07902713
- Testing
- Becotatug Vedotin (MRG003), Gemcitabine (1000 mg/m2), Camrelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancers, Head and Neck Cancers - Nasopharyngeal
Predictive Tools in Head and Neck Cancer Patients Undergoing Radiotherapy
The ITHACA study aims to improve the treatment of head and neck cancer by developing a predictive tool that helps doctors personalize care for each patient.
- Conditions
- Head and Neck Cancers, Head and Neck Cancers - Nasopharyngeal, Oral Cavity Cancer, Oropharyngeal Cancers
- Trial name
- ITHACA (NCT06806683)
- Testing
- intensity modulated radiotherapy
- Where
- Italy
- Volunteers
- 915 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma
This trial aim to explore whether short-course tislelizumab (3 cycles of 200 mg q3w in the induction phase and 3 cycles of 400 mg q6w in the consolidation phase) yields non-inferior event-free survival compared to long-course…
- Trial name
- NCT07373990
- Testing
- tislelizumab, Gemcitabine + cisplatin (GP), Cisplatin (100mg/m2)
- Volunteers
- 418 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma
The primary objective of this study is to determine the overall survival in patients with stage II (T1-2N1M0) NPC treated with concurrent chemotherapy and radiotherapy.
- Trial name
- NCT00817258
- Testing
- cisplatin, 3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fudan University
Nasopharyngeal Neoplasms, Stomatitis
Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT
Radiation therapy remains the principal treatment for nasopharyngeal carcinoma (NPC). The most frequently occurred radiation-related side effect is probably the radiation-induced oral mucositis (OM), which affects up to 100% of…
- Trial name
- NCT02735317
- Testing
- Oral Ulcer Gargle (FORRAD®), Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Yun-fei Xia
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It may also stop the growth of tumor cells by stopping blood flow to the tumor.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00096512
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy
The aim of this study is to define the efficacy and safety of Fluzoparib and Camrelizumab in treating patients with recurrent/metastatic nasopharyngeal carcinoma that progressed after first-line chemotherapy.
- Trial name
- NCT04978012
- Testing
- Fluzoparib and Camrelizumab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fudan University
Head and Neck Cancer
Vaccine Therapy in Treating Patients With Head and Neck Cancer
RATIONALE: Vaccines made from a person's dendritic cells mixed with peptides may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00404339
- Testing
- mutant p53 peptide pulsed dendritic cell vaccine, tetanus toxoid helper peptide, adjuvant therapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Robert Ferris
Nasopharyngeal Carcinoma, Brain Necrosis
Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis
It is hypothesized that excessive generation of free radicals involves in the pathogenesis of radiation-induced brain necrosis. This study therefore evaluated the effect of free radical scavenger, edaravone, on radiation-induced…
- Trial name
- NCT01865201
- Testing
- Edaravone, Common fundamental management
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.